Nextera

Executive Summary

Nextera is a Norwegian drug and target discovery company spun out from a Centre of Excellence at Oslo University Hospital. Its proprietary NextCore platform enables the development of TCR-like antibodies targeting pHLA complexes, offering a novel approach for cancer, autoimmune, and inflammatory diseases. The platform aims to unlock previously undruggable targets by mimicking T-cell receptor specificity, potentially expanding the therapeutic landscape beyond conventional antibodies. Nextera's strategy centers on discovering novel targets and advancing precision immunotherapies through partnerships with other organizations. By leveraging its core technology, the company seeks to de-risk development and accelerate clinical translation. As a private entity with limited public data, its near-term value hinges on securing strategic collaborations and validating its platform through preclinical data. If successful, Nextera could become a key player in the TCR-like antibody space, addressing significant unmet needs in immunology and oncology.

Upcoming Catalysts (preview)

• TBDStrategic partnership or licensing deal for a NextCore-derived candidate40% success
• Q1 2027Presentation of preclinical proof-of-concept data at a major immunology conference50% success
• TBDAnnouncement of platform expansion into new disease areas or target classes60% success